Both anti-TIGIT domvanalimab-containing arms in the ARC-7 study continued to show meaningful differentiation compared to the anti-PD1 antibody zimberelimab alone for first-line metastatic non-small cell lung cancer (NSCLC).

Arcus and Gilead are expanding their late-stage clinical program for domvanalimab, aiming to establish a best-in-class PD-1 + TIGIT antibody backbone and triplet regimens.

The third registrational Phase 3 study, STAR-121, will evaluate domvanalimab plus zimberelimab and chemotherapy versus pembrolizumab with chemotherapy in first-line NSCLC PD-L1 all-comers, expected to initiate in 4Q 2022.

Arcus is well positioned to advance its programs with $1.3 billion in cash and cash equivalents, providing funding into 2026.